Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study

BACKGROUND: Regorafenib is a multi-kinase inhibitor, which was shown to be effective for patients with metastatic colorectal cancer refractory to standard therapies. However, its patterns of response has not yet been fully understood. METHODS: Clinical records of 10 patients who received regorafenib...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Ozaki, Yukinori, Shindoh, Junichi, Gonoi, Wataru, Nishioka, Yujiro, Kondoh, Chihiro, Tanabe, Yuko, Matoba, Shuichiro, Kuroyanagi, Hiroya, Hashimoto, Masaji, Takano, Toshimi
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800281/
https://ncbi.nlm.nih.gov/pubmed/29402244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4067-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi